Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Number of holders
-
65
-
Total 13F shares, excl. options
-
50,808,497
-
Shares change
-
+2,712,136
-
Total reported value, excl. options
-
$415,724,914
-
Value change
-
+$29,078,237
-
Number of buys
-
36
-
Number of sells
-
-19
-
Price
-
$8.19
Significant Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q3 2017
72 filings reported holding ADAPY - Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share as of Q3 2017.
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) has 65 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50,808,497 shares
of 1,571,428,571 outstanding shares and own 3.2% of the company stock.
Largest 10 shareholders include Matrix Capital Management Company, LP (12,043,511 shares), NEA Management Company, LLC (12,025,999 shares), Capital World Investors (6,792,700 shares), FMR LLC (4,967,550 shares), ORBIMED ADVISORS LLC (1,914,660 shares), BAILLIE GIFFORD & CO (1,379,304 shares), RENAISSANCE TECHNOLOGIES LLC (1,155,100 shares), Tekla Capital Management LLC (935,368 shares), Rock Springs Capital Management LP (875,000 shares), and QVT Financial LP (859,392 shares).
This table shows the top 65 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.